Benzinga | Aug 10, 2021 08:08AM EDT

Morgan Stanley Downgrades Epizyme to Underweight, Lowers Price Target to $5

Morgan Stanley analyst David Lebowitz downgrades Epizyme (NASDAQ:EPZM) from Equal-Weight to Underweight and lowers the price target from $10 to $5.